Eloxx Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $84.86M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 3, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | During market hours | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | Apr 4, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 9, 2021 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 17, 2021 | After market close | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 7, 2021 | After market close | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Mar 11, 2021 | During market hours | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 5, 2020 | During market hours | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Aug 6, 2020 | Before market open | – | – | – |
Press releases
Announcements Eloxx Pharmaceuticals filed with the SEC
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
RARE Thinking for RARE Solutions
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Reports Topline Results
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RARE Thinking for RARE Solutions Topline ELX - 02 Combination Phase 2 Cystic Fibrosis (CF) Results September 14, 2022
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Eloxx Pharmaceuticals Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Announces Changes to Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Quarter 2021 Financial and Operating Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Eloxx Pharmaceuticals Reports Positive Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RARE Thinking for RARE Solutions Topline ELX - 02 Phase 2 Cystic Fibrosis Results November 17, 2021
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Eloxx Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K